SEQUENTIAL METHOTREXATE, 5-FLUOROURACIL (5-FU), AND HIGH-DOSE LEUCOVORIN VERSUS 5-FU AND HIGH-DOSE LEUCOVORIN VERSUS 5-FU ALONE FOR ADVANCED COLORECTAL-CANCER - A MULTIINSTITUTIONAL RANDOMIZED TRIAL

被引:0
|
作者
ABAD, A
GARCIA, P
GRAVALOS, C
TUSQUETS, I
FONT, A
PEREZ, G
CORTESFUNES, H
FABREGAT, X
BARNADAS, A
ROSELL, R
机构
[1] HOSP GEN GREGORIO MARANON,DEPT MED ONCOL,MADRID,SPAIN
[2] HOSP 12 OCTUBRE,DEPT MED ONCOL,E-28041 MADRID,SPAIN
[3] HOSP DEL MAR,DEPT MED ONCOL,BARCELONA,SPAIN
关键词
FLUOROURACIL; 5-FU; BIOCHEMICAL MODULATION; COLORECTAL CANCER;
D O I
10.1002/1097-0142(19950315)75:6<1238::AID-CNCR2820750605>3.0.CO;2-P
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. The primary objective of this study was to compare the single-biochemical modulation of 5-fluorouracil (5-FU) and leucovorin with that of the double-biochemical modulation of methotrexate and leucovorin. Because of the Martin et al. study in which an experimental model showed similar effects of 5-FU at maximum tolerated doses to the modulation with leucovorin at standard doses, a third treatment arm of 5-FU alone was also studied. Methods. A randomized trial was performed using a 500-mg/m(2) intravenous (i.v,) 1-hour infusion of methotrexate, and 12 hours later, a 600-mg/m(2) i.v. bolus of 5-FU plus a 200-mg/m(2) i.v. 1-hour infusion of leucovorin (MFL) every 2 weeks versus 5-FU plus leucovorin at an equal dose and schedule (FL), versus a 1200-mg/m(2) i.v dose of 5-FU every 2 weeks. Of 186 patients included in the study, 178 were evaluable. Results. In a preliminary analysis with 94 evaluable patients, two significant statistical differences were shown. First, the toxicity rate of the 5-FU-alone (F) treatment arm was higher than that of the other arms (MFL vs. F, P = 0.0002; FL vs. F, P = 0.00001). Second, the median survival was worse in the F treatment arm with a rate of 12.6 months for the MFL and FL arms and 7.5 months for the F arm (P < 0.05). Considering these results, the F treatment arm was discontinued. The final results included 70 evaluable patients for MFL and 74 patients for FL. No difference was found in the distribution of prognostic factors. The response rates were 25.7% for MFL (95% CI, 16-37.5) and 14.8% for FL (95% CI, 7.6-25), (P = 0.1). The median survival was 14.3 months for patients treated with MFL and 12.3 months for those treated with FL. The hematologic toxicity was mild, with no grade 3/4 leukopenia in either treatment arm. The major nonhematologic toxicity in the MFL and FL treatment arms was ocular; nongrade 3/4 diarrhea also was observed. Conclusions. The results of MFL double-biochemical modulation failed to show a significant statistical difference from that of single-biochemical modulation for this dose and schedule.
引用
收藏
页码:1238 / 1244
页数:7
相关论文
共 50 条
  • [31] WEEKLY REGIMEN OF 5-FU VS 5-FU PLUS INTERMEDIATE DOSE FOLINIC ACID IN THE TREATMENT OF ADVANCED COLORECTAL-CANCER
    MARTONI, A
    CRICCA, A
    GUARALDI, M
    COVIZZI, M
    FARRIS, A
    PANNUTI, F
    ANTICANCER RESEARCH, 1992, 12 (03) : 607 - 612
  • [32] Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial)
    Duffour, Jacqueline
    Bouche, Olivier
    Rougier, Philippe
    Milan, Chantal
    Bedenne, Laurent
    Seitz, Jean-Francois
    Buecher, Bruno
    Legoux, Jean-Louis
    Ducreux, Michel
    Vetrer, Denis
    Raoul, Jean-Luc
    Francois, Eric
    Ychou, Marc
    ANTICANCER RESEARCH, 2006, 26 (5B) : 3877 - 3883
  • [33] A PHASE-II TRIAL OF INTENSIVE COURSE 5-FLUOROURACIL (5-FU) PLUS HIGH-DOSE CIS-PLATINUM (CDDP) IN ADVANCED COLORECTAL-CANCER
    OCONNELL, MJ
    MOERTEL, CG
    KVOLS, LK
    HAHN, RG
    RUBIN, J
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1985, 26 (MAR): : 166 - 166
  • [34] Economical evaluation of raltitrexed versus fluorouracil plus leucovorin (5-FU + LV) for treatment of advanced colorectal cancer
    Vorobyov, P
    Sura, M
    Avxentieva, M
    Papsheva, V
    VALUE IN HEALTH, 2002, 5 (06) : 538 - 538
  • [35] Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU
    Gamelin, EC
    DanquechinDorval, EM
    Dumesnil, YF
    Maillart, PJ
    Goudier, MJ
    Burtin, PC
    Delva, RG
    Lortholary, AH
    Gesta, PH
    Larra, FG
    CANCER, 1996, 77 (03) : 441 - 451
  • [36] SEQUENTIAL CHEMOTHERAPY OF 5-FLUOROURACIL (5-FU) AND METHOTREXATE (MTX) IN THE REGIMEN OF CYTOXAN (CTX), MTX AND 5-FU IN THE TREATMENT OF ADVANCED BREAST-CANCER
    CHANG, JC
    HILL, G
    EDISS, G
    REILING, W
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 404 - 404
  • [37] 5-FLUOROURACIL(5-FU) IN PRIMARY TRABECULECTOMY - A RANDOMIZED TRIAL
    LOFTFIELD, K
    BALL, SF
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1991, 32 (04) : 745 - 745
  • [38] Intraoperative 5-fluorouracil (5-FU) with postoperative 5-FU injections versus postoperative injections only in primary trabeculectomies
    Urken, SI
    Skuta, GL
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1996, 37 (03) : 117 - 117
  • [39] High-dose chronomodulated infusion of 5-fluorouracil (5-FU) and folinic acid (FA) (FF5-16) in advanced colorectal cancer patients
    Terzoli, E
    Garufi, C
    Zappalà, AR
    Vanni, B
    Pugliese, P
    Cappellini, GA
    Aschelter, AM
    Perrone, M
    Giannarelli, D
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2004, 130 (08) : 445 - 452
  • [40] High-dose chronomodulated infusion of 5-fluorouracil (5-FU) and folinic acid (FA) (FF5–16) in advanced colorectal cancer patients
    Edmondo Terzoli
    Carlo Garufi
    Albina Rita Zappalà
    Barbara Vanni
    Patrizia Pugliese
    Giancarlo Antonini Cappellini
    Anna Maria Aschelter
    Maria Perrone
    Diana Giannarelli
    Journal of Cancer Research and Clinical Oncology, 2004, 130 : 445 - 452